Product news from the 04/28/06 News Brief

Share this article:
Bristol-Myers Squibb and Gilead Sciences have submitted a new drug application to the FDA for approval of a product combining the anti-HIV medications Sustiva (efavirenz), manufactured by Bristol-Myers Squibb, and Truvada (emtricitabine and tenofovir disoproxil fumarate), manufactured by Gilead in a once-daily single tablet regimen. If approved by the FDA, the new single tablet regimen would be the first and only product that contains a complete highly active antiretroviral therapy regimen in a single once-daily tablet, the companies said. Novartis announced its new drug application (NDA) for Exforge (amlodipine besylate/valsartan) was accepted for standard review by the FDA as a new treatment option for people with high blood pressure. The submission for EU approval was completed earlier in 2006. The FDA this week issued a safety alert not to administer drugs containing promethazine hydrochloride to children younger than 2, citing seven cases of death linked to use of the antihistamine. The agency said it has also received 22 reports of severe breathing problems associated with the use of the drug—all in children younger than 2. Promethazine HC1 is sold by Wyeth as Phenergan and is available in various generic versions. The warning covers all forms of the drug, including syrups, suppositories, tablets and injectable liquids. Labels on all versions of the drug have been updated to reflect strengthened warnings, the FDA said. Promethazine hydrochloride was approved by the FDA in 1951 and is used to treat hay fever and a stuffy or runny nose due to allergies.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.